Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $355.2 million.

  • Agios Pharmaceuticals' Non-Current Assets fell 4908.64% to $355.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 24.23%. This contributed to the annual value of $355.2 million for FY2025, which is 4908.64% down from last year.
  • According to the latest figures from Q4 2025, Agios Pharmaceuticals' Non-Current Assets is $355.2 million, which was down 4908.64% from $352.6 million recorded in Q3 2025.
  • Agios Pharmaceuticals' Non-Current Assets' 5-year high stood at $717.6 million during Q3 2024, with a 5-year trough of $103.3 million in Q4 2023.
  • For the 5-year period, Agios Pharmaceuticals' Non-Current Assets averaged around $352.1 million, with its median value being $357.4 million (2023).
  • In the last 5 years, Agios Pharmaceuticals' Non-Current Assets tumbled by 7455.75% in 2023 and then soared by 57542.48% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Non-Current Assets (Quarter) stood at $373.5 million in 2021, then increased by 8.69% to $405.9 million in 2022, then plummeted by 74.56% to $103.3 million in 2023, then soared by 575.42% to $697.6 million in 2024, then tumbled by 49.09% to $355.2 million in 2025.
  • Its Non-Current Assets stands at $355.2 million for Q4 2025, versus $352.6 million for Q3 2025 and $451.8 million for Q2 2025.